

October 14, 2026

Key Indices Update

Indices	Close	Change (%)
Nifty	22,721.95	1.60 ↗
Sensex	73,033.78	1.54 ↗
Midcap	59,459.20	1.06 ↗
Smallcap	19,447.40	0.11 ↗

Trend Strength Indicator

Nifty 50 Stocks above 200	NSE Advance / Decline
11	2127 / 1417

Key Data

Data	Current	Previous
Dow Jones	51654.95	51942.85
U.S. Dollar Index	102.18	102.48
Brent Crude (USD/ BBL)	107.06	105.68
US 10Y Bond Yield (%)	5.23	5.21
India 10Y Bond Yield (%)	7.36	7.39

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	55449.55	0.97 ↗
NIFTYAUTO	25332.10	0.99 ↗
NIFTYENERG	35880.45	0.06 ↗
NIFTYFINSR	27112.25	1.08 ↗
NIFTYFMCG	44574.00	1.04 ↗
NIFTYIT	29739.10	4.90 ↗
NIFTYMEDIA	1631.45	0.41 ↗
NIFTYMETAL	12053.25	0.85 ↗
NIFTYPHARM	26029.45	0.19 ↘
NIFTYREALT	827.50	2.15 ↗

Fundamental

Refer Page 02

Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
TVSSCS	Logistics	126	165	30.6%

*CMP as on October 13 2026

Top News

- ✦ **M&M has commenced production of MaxSeeder, a licensed zero-till multi-crop seeder developed with Clean Seed Technologies, Canada.** The machine reduces stubble burning, seed and fertiliser wastage, conserves water and supports sustainable farming.
- ✦ **Sun Pharma's Board has approved issuing listed, rated, unsecured, redeemable non-convertible debentures worth up to ₹10,000 crore through private placement, in one or more tranches or series,** subject to applicable regulatory requirements.

Technical

Refer Page 03-04

- ✦ **Nifty staged a strong recovery on Tuesday,** gaining over one and a half percent and extending the rebound amid the prevailing consolidation phase.
- ✦ From a technical perspective, **the Nifty's recovery above 22,700 offers near-term relief following the recent sharp correction.**
- ✦ **However, the 22,900 level, coinciding with the 20-day exponential moving average (20-DEMA),** is likely to act as the immediate hurdle, followed by the 23,000–23,200 zone.
- ✦ On the downside, **the 22,300–22,500 zone is likely to provide immediate support.**
- ✦ Despite the sharp rebound, **persistent macroeconomic uncertainties warrant a cautious approach,** with a preference for selective stock-specific opportunities and disciplined risk management.
- ✦ **Stock of the day - HAL**

Fundamental

Top News

01

M&M has commenced production of MaxSeeder, a licensed zero-till multi-crop seeder developed with Clean Seed Technologies, Canada. The machine reduces stubble burning, seed and fertiliser wastage, conserves water and supports sustainable farming.

02

Sun Pharma's Board has approved issuing listed, rated, unsecured, redeemable non-convertible debentures worth up to ₹10,000 crore through private placement, in one or more tranches or series, subject to applicable regulatory requirements.

03

Jubilant Pharmova saw Abakkus Asset Managers, through its Abakkus Four2Eight Opportunities Fund, acquire an additional 0.69% stake by purchasing 11 lakh shares from Quant Mutual Fund for approximately ₹100.65 crore at an average price of ₹915 per share.

04

Karur Vysya Bank has partnered with Zurich Kotak General Insurance Company to distribute general insurance products to its customers, strengthening its bancassurance offerings as part of its regular banking and customer service activities.

05

Lenskart Solutions saw Alpha Wave Global divest a 1.51% stake, equivalent to around 2.64 crore shares, for ₹1,704.79 crore through an open market transaction at ₹645.31 per share. Earlier, the investor sold a 1.69% stake worth approximately ₹1,856.78 crore.

Stock for Investment

TVS Supply Chain Solutions Limited

Stock Symbol TVSSCS

Sector Logistics

***CMP (₹)** 126

^Target Price (₹) 165

Upside 30.6%

*CMP as on October 13 2026

^Time horizon - upto 11 Months

- ✦ **Strong Q1FY27:** Revenue grew 28.7% YoY to ₹3,335cr, while EBITDA/PAT rose 34%/156% YoY.
- ✦ **ISCS Margin Recovery:** ISCS revenue grew 21.9% YoY to ₹2,417cr. Margins are expected to improve to 9.5–10% by Q4FY27 as transition costs normalize.
- ✦ **Strong Visibility:** Record Q1 wins of ₹543cr and a ₹7,500+cr pipeline provide healthy revenue visibility. GFS EBITDA margin improved to 4.1%.
- ✦ **Growth & Outlook:** ALA JV and Swami & Sons support diversification. FY26–28E Revenue/EBITDA/PAT CAGR of 12.5%/17.5%/18.5%; BUY, TP ₹165.

Technical

Inching towards 20 DEMA. Stay selective.

NIFTY

22721.95 ▲ 358.60 (1.60%)

S1

22500

S2

22300

R1

22900

R2

23100

Technical Chart : Daily



- ✦ **Nifty staged a strong recovery on Tuesday**, gaining over one and a half percent and extending the rebound amid the prevailing consolidation phase.
- ✦ From a technical perspective, **the Nifty's recovery above 22,700 offers near-term relief following the recent sharp correction.**
- ✦ **However, the 22,900 level, coinciding with the 20-day exponential moving average (20-DEMA), is likely to act as the immediate hurdle, followed by the 23,000–23,200 zone.**
- ✦ Despite the sharp rebound, **persistent macroeconomic uncertainties warrant a cautious approach**, with a preference for selective stock-specific opportunities and disciplined risk management.

BANKNIFTY

55481.05 ▲ 563.05 (1.03%)

S1

55000

S2

54400


R1

56000

R2

56500

Technical Chart : Daily



- ✦ **The banking index extended its relief rally**, recovering from the previous session's correction and closing above the 20 DEMA, signalling improving short-term momentum.
- ✦ **The index opened firmly and sustained buying interest throughout the session, ended near day's high.**
- ✦ **Sectoral participation remained mixed**, with IndusInd Bank and Yes Bank showing relative resilience, while Kotak Bank and IDFC First Bank underperformed.
- ✦ **Immediate resistance is placed near 56,500, while crucial support remains around 54,400.**

Technical

Stock of the day

HAL

Recom.

BUY

CMP (₹)

4869

Range*

4860-4870


SL

4690

Target

5200

Technical Chart : Weekly



- ✦ **HAL is demonstrating a constructive bullish setup**, having decisively reclaimed and closed above the 20 and 50 DEMA, supported by expanding volumes.
- ✦ **The recent breakout above the declining trendline indicates strengthening momentum**, with prices sustaining above the breakout zone.
- ✦ **Higher highs and higher lows reinforces improving demand** and strengthens the positive price structure, favoring further recovery.
- ✦ **Traders may consider accumulating the stock** within the recommended range.

Momentum Stocks Midcap

Name	Price	Price %
PNCINFRA	155.70	12.61↑
TANLA	535.00	7.21↑
KPITTECH	513.75	6.81↑
GREENPANEL	150.45	2.29↓
GSPL	268.35	7.13↓

Name	Price	Price %
HCLTECH	1318.50	7.81↑
INFY	1060.70	3.99↑
PERSISTENT	5991.00	3.53↑
CGPOWER	853.25	1.64↓
RBLBANK	389.00	6.87↓

Range Breakout/ Breakdown

Top 5 F&O Gainers ↑

Name	Price	Price %
BANDHANBNK	172.24	9.36↑
HCLTECH	1318.50	7.81↑
KPITTECH	513.75	6.81↑
TCS	2258.00	6.26↑
SHRIRAMFIN	985.75	6.06↑

Name	Price	Price %
RBLBANK	389.00	6.87↓
POWERINDIA	30195.00	3.50↓
VEDL	255.90	3.40↓
ICICIPRULI	448.10	3.30↓
MCX	3302.70	2.58↓

Top 5 F&O Losers ↓

Bullish Charts

Name	Price	Price %
CROMPTON	211.60	4.49↑
LTM	4202.80	4.58↑
TATAELXSI	3416.40	4.89↑
TECHM	1538.60	4.60↑
WAAREENER	2453.20	4.61↑

Name	Price	Price %
CGPOWER	853.25	1.64↓
DIVISLAB	9260.00	1.76↓
HINDPETRO	326.30	1.79↓
JSWENERGY	459.50	1.68↓
POLYCAB	8280.00	1.49↓

Bearish Charts

Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Rajan Gupta	rajan.gupta1@religare.com
Vivek Chandra	vivek.chandra@religare.com
Himanshu Gupta	himanshu.gupta1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes: Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results

